Seres therapeutics to host second quarter 2016 financial results and operational progress conference call and webcast on august 11, 2016

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq:mcrb), a leading microbiome therapeutics platform company, today announced that management will host a conference call and live audio webcast on thursday, august 11, 2016 at 8:30 a.m. et to discuss second quarter 2016 results. to access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference id number 60863839. to join the live webcast please visit the “investors and media” section of the seres website at www.serestherapeutics.com. a webcast replay will be available on the seres website beginning approximately two hours after the event and will be archived for 21 days. about seres therapeutics seres therapeutics, inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. seres’ program ser-109 continues to be evaluated in a phase 2 study in multiply recurrent cdi. seres’ second clinical candidate, ser-287, is being evaluated in a phase 1b study in patients with mild-to-moderate ulcerative colitis (uc). seres is also developing ser-262, the first ever synthetic microbiome therapeutic candidate, in a phase 1b study in patients with primary cdi. for more information, please visit www.serestherapeutics.com. follow us on twitter @serestx.
MCRB Ratings Summary
MCRB Quant Ranking